• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

E-cig vapor does not induce genetic mutations associated with cigarette smoke exposure

Bioengineer by Bioengineer
November 4, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

E-cigarette vapour does not induce DNA mutations commonly observed with tobacco smoke exposures in lab-based tests.

Scientists at British American Tobacco used a method called the Ames test to compare the mutagenic potential of cigarette smoke with that of vapour from Vype ePen, a commercially available e-cigarette. DNA mutations result in genetic instability, which may be involved in the development of cancer.

The Ames test is widely used method that uses bacteria to test whether a given chemical or drug causes mutations in the bacteria's DNA. The standard test involves five bacterial strains. In this study, two of these bacteria were used Salmonella typhimurium strains TA98 and TA100, both of which are effective at screening 90-95% of potential mutagens. TA98 and TA100 have been used widely to assess tobacco smoke, but never for the assessment of freshly generated e-cigarette aerosols, until now.

Traditionally, the particulate matter in smoke is assessed, but this is only a small fraction of the tobacco smoke. To more accurately reflect real-life exposure, whole smoke was also tested. In all, the researchers tested both the particulate matter and whole aerosol of smoke from a reference cigarette 3R4F and vapour from Vype ePen.

To do this, they trapped particulate matter from smoke or vapour on a filter pad and then washed the pad with a solvent to produce a stock solution that could be diluted into various concentrations. They then exposed the test bacteria to the same concentrations of either smoke or vapour extract. They also exposed test bacteria to freshly generated smoke or e-cigarette vapour.

Exposure to smoke was seen to cause mutations in both bacterial strains in a dose-dependent manner – the higher the dose, the higher the mutation rate. Whole smoke took just 24 minutes to cause mutations. E-cigarette vapour extracts, gave no response, and whole vapour did not cause the bacteria to mutate, even after three hours of continuous exposure, which was comparable to the results obtained from air and untreated controls.

'These findings suggest that Vype ePen vapour does not induce the mutations observed on exposure to smoke,' said Dr James Murphy, Head of Reduced Risk Substantiation at British American Tobacco. 'This study adds data to support the growing evidence base that e-cigarettes have the potential to be significantly less harmful compared to cigarette smoke, though more research is needed' he said.

Many in the public health community believe e-cigarettes offer great potential for reducing the public health impact of smoking. Public Health England, an executive body of the UK Department of Health, recently published a report saying that e-cigarettes are 95% safer than cigarettes. The Royal College of Physicians have said that the public can be reassured that e-cigarettes are much safer then smoking and that they should be widely promoted as an alternative to cigarettes, but called for more research to be done on the potential long term effects of using e-cigarettes.

###

The results are published in Mutation Research/Genetic Toxicology and Environmental Mutagenesis.

Media Contact

Marina Murphy
[email protected]
44-077-111-50135
@BAT_Sci

http://www.bat-science.com

Share13Tweet7Share2ShareShareShare1

Related Posts

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

September 7, 2025

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

September 7, 2025

FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC

September 7, 2025

Ivonescimab Combined with Chemotherapy Enhances Progression-Free Survival in EGFR-Positive NSCLC Patients After Third-Generation EGFR-TKI Treatment

September 7, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    55 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.